Does Aetna (CVS Health) Cover Wegovy? Prior Authorization, Formulary Tier, and Appeal Steps

Wegovy delivers semaglutide 2.4 mg as a once-weekly injection under the skin and belongs to a drug class called GLP-1 receptor agonists. The FDA cleared Wegovy for long-term weight control in adults who have obesity (BMI of 30 or higher) or are overweight (BMI of 27 or higher) plus a weight-related health issue like high blood pressure, type 2 diabetes, or high cholesterol; the agency later approved it for teenagers 12 years and up who meet the same weight thresholds. Although Wegovy contains the same active ingredient as Ozempic (semaglutide 1 mg for type 2 diabetes) and Rybelsus (a tablet form of semaglutide), they are distinct products with different approved uses.

Aetna, whose pharmacy benefits are administered through CVS Caremark, generally treats Wegovy as a covered but restricted drug on commercial plans: it typically sits behind prior authorization and step therapy rather than being excluded outright. The specific documentation gate, formulary tier, and copay a given member faces depends on their individual plan document, not on a single company-wide policy, and self-funded employer plans in particular can differ sharply from Aetna's own fully-insured products. That plan-level variability is the most important thing to understand before assuming any number below applies to you.

The direct answer, and its limits

Most Aetna commercial PPO and HMO members can get Wegovy covered if they meet FDA-label BMI or BMI-plus-comorbidity criteria, document a period of lifestyle intervention, and in many cases show a documented trial or contraindication to a lower-cost anti-obesity medication first. This pattern is consistent with how commercial payers generally manage high-cost GLP-1 weight-loss drugs, and it lines up with the FDA label's own eligibility criteria and dose-titration schedule. What is not established from public sources is a single, fixed Aetna-wide prior authorization form, tier assignment, or copay figure that applies to every member; those details live in your plan's specific formulary and Summary of Benefits and Coverage (SBC), and they change over time. If a number below (a copay range, a review timeline, a tier) does not match what your plan portal or CVS Caremark tells you, treat your own plan document as authoritative.

What is established, what is typical, and what needs verification

Established from the FDA label and regulatory record:

• Wegovy is FDA-approved for chronic weight management in adults with the BMI criteria above, and in adolescents 12 and older meeting weight criteria (FDA label, approved June 2021, label updated since).
• The FDA-recommended dose-titration schedule increases from 0.25 mg to a 2.4 mg maintenance dose over about 16 weeks, and the label directs prescribers to reassess treatment in patients who have not lost at least 5% of body weight after reaching a stable dose.
• Under the Affordable Care Act, members of ACA-regulated plans have a right to an independent external review after exhausting a plan's internal appeal, and that external decision is binding on the insurer (CMS overview of external appeals).

Typical industry practice, plausible but not confirmed as Aetna's current specific policy in this review:

• Prior authorization requiring documented BMI, comorbidity, and a period of supervised lifestyle intervention.
• Step therapy requiring a documented trial or contraindication to an older, lower-cost anti-obesity medication (phentermine, phentermine-topiramate, or naltrexone-bupropion are commonly used as step agents across payers).
• Specialty-tier placement (commonly Tier 4 or 5) with higher coinsurance or copay than preferred-brand drugs.
• Reauthorization tied to a minimum weight-loss threshold, often cited industry-wide as around 5% body weight loss, at renewal.

Not established here and requiring direct verification with Aetna or CVS Caremark:

• The exact current PA form, required attachments, and turnaround time for your specific plan.
• Precise dollar copay or coinsurance amounts, since these depend on your plan design, deductible status, and whether your employer negotiated different terms.
• Whether your specific self-funded employer plan even includes an anti-obesity medication benefit; some employer plans exclude the entire drug class regardless of Aetna's default policy.

Prior authorization: what prescribers generally need to submit

Across commercial payers, PA requests for Wegovy commonly need to show: a measured (not self-reported) height and weight producing the qualifying BMI, a documented obesity or overweight-with-comorbidity diagnosis, evidence of a structured diet and exercise effort over a period of months, and, where step therapy applies, documentation that a lower-cost agent was tried and failed or is contraindicated. The Endocrine Society's clinical practice guideline on pharmacological obesity management supports using medication as an adjunct to lifestyle change once BMI thresholds are met, which is the general clinical logic payers cite when structuring these requirements, though the guideline itself does not set Aetna's specific paperwork requirements.

A frequent reason PA requests stall is vague documentation, such as a chart note that only says "advised diet and exercise" without dates, measurements, or outcomes. Serial weight measurements across visits and a clear statement of which step-therapy medication was used, at what dose, for how long, and why it was insufficient, strengthens a request considerably more than a general statement of medical necessity.

Standard PA decisions for specialty drugs across payers commonly take one to three weeks, with expedited review available in 24 to 72 hours when a clinician documents urgency. Confirm the current standard and expedited timeframes for your specific plan with CVS Caremark, since exact turnaround times are not fixed by regulation for all situations and can vary.

Formulary tier and what you might pay

Wegovy is a specialty-tier drug on most commercial formularies, including Aetna's, which generally means higher out-of-pocket costs than preferred generic or brand drugs. The unassisted list price is set by the manufacturer and has been reported publicly in the $1,300 per month range for a four-week supply, though list prices change and should be confirmed against current manufacturer pricing rather than treated as fixed.

What you actually pay depends heavily on plan design:

• A fixed specialty copay plan might charge a flat amount per fill.
• A coinsurance plan charges a percentage of the drug's cost, which can be substantial before the deductible is met.
• A high-deductible health plan generally requires paying close to the full negotiated price until the deductible is satisfied.

Observational research on GLP-1 weight-loss medications has associated higher out-of-pocket costs with higher rates of stopping treatment, which is one practical reason to understand your likely cost before starting rather than after the first large pharmacy bill. The exact magnitude of that association reported in any single study should be checked against the primary publication before being repeated as a specific statistic; this article does not carry a verified number for that effect.

Step therapy: the logic and the exceptions

Step therapy asks a patient to try a lower-cost anti-obesity medication before an insurer will pay for a more expensive one. Commonly accepted step agents include phentermine (short-term use), phentermine-topiramate extended release, and naltrexone-bupropion extended release, each generally requiring a documented trial period before being called a failure. "Failure" in most payer frameworks means inadequate weight loss during the trial, intolerable side effects, or a documented medical contraindication.

Step therapy is a real barrier for some patients, and clinical experience suggests a meaningful minority of patients do respond adequately to these older agents, which is the rationale payers use for requiring the trial. For patients who cannot safely use any step agent (for example, a seizure history ruling out naltrexone-bupropion, cardiovascular disease limiting phentermine, and a contraindication to topiramate all in the same patient), most payers, including Aetna, allow a documented exception request submitted alongside the PA rather than requiring an unsafe trial. This exception pathway is a genuinely underused option: prescribers sometimes default to starting the step-therapy trial anyway rather than documenting why it should be waived.

A decision framework for an Aetna Wegovy denial or delay

Use this to decide your next concrete step rather than restarting the whole process from scratch each time something changes.

Appealing a denial

If Aetna denies the PA, a first-level internal appeal is the next step, generally filed within the plan's stated deadline (commonly around 180 days, though the exact window is set by your plan document). An effective appeal directly answers the specific reason listed in the denial letter rather than restating general medical necessity. If the denial cites incomplete lifestyle documentation, attach the missing records. If it cites incomplete step therapy, attach dated records of the trial or the contraindication argument for an exception.

If the internal appeal is also denied, ACA-regulated plans give members the right to an independent external review, where an outside reviewer applies the same clinical criteria and their decision binds the insurer. General reporting from state insurance regulators has described meaningful overturn rates for specialty-drug denials at external review, though a precise, current, drug-specific overturn rate for anti-obesity medications specifically was not available in the sources used for this article and should not be treated as a fixed percentage.

A strong appeal letter typically references the patient's BMI history, the comorbidities that could improve with weight loss, and the documented failure or contraindication of prior interventions with specific dates and doses. Clinicians experienced in obesity medicine generally describe persistence and specificity, not volume, as what moves an appeal: a short letter that answers the exact denial reason with dated records tends to outperform a long general letter that does not.

The manufacturer savings card

Commercially insured patients (not those on Medicare, Medicaid, or other government-funded coverage) may qualify for a Novo Nordisk savings card that reduces the copay for a limited number of fills per year, subject to a per-fill maximum benefit that changes periodically. The card covers the gap between your plan's cost-sharing and the benefit cap, so if your coinsurance leaves a large monthly balance, the card will reduce it rather than eliminate it. Check the manufacturer's current terms directly before assuming a specific dollar figure, since these programs are revised over time and this article does not carry a verified current cap.

Reauthorization

Initial PA approvals for anti-obesity medications commonly run six to twelve months before a reauthorization review, and payers typically look for a minimum percentage of body weight lost during that window, often cited industry-wide as around 5%, before renewing coverage. The FDA label itself directs a clinical reassessment for patients who have not lost at least 5% of body weight after reaching the maintenance dose, which is the clinical rationale behind that renewal threshold, though the exact percentage and review window used by any specific Aetna plan should be confirmed against your plan's own reauthorization criteria. Patients who fall short of the threshold are not automatically dropped in every case; documented reasons such as a drug shortage interrupting supply, a dose-titration delay, or an intercurrent illness can sometimes support continued coverage, but this depends on the plan and should be discussed directly with the prescriber's office before assuming denial is inevitable.

Medicare Advantage and Medicaid: different rules

Aetna Medicare Advantage and Medicaid managed-care plans follow different coverage frameworks than commercial plans. Medicare Part D historically excluded anti-obesity medications, and coverage has been expanding under federal policy changes affecting Part D plans, but individual Aetna Medicare Advantage plans may still apply narrower BMI criteria, specialist referral requirements, or fill limits beyond what a commercial plan requires. Medicare Advantage members are also not eligible for the manufacturer savings card. Medicaid coverage of GLP-1 anti-obesity medications varies substantially by state, and the number of states covering these drugs has been reported as a minority as of recent surveys, though that figure changes as state policy evolves; anyone on an Aetna Medicaid managed-care plan should confirm current coverage directly with their state plan rather than relying on a national estimate.

When to involve your prescriber urgently rather than waiting on an appeal

Coverage delays and appeals are administrative processes, not medical ones. If you experience symptoms while on or coming off Wegovy that could signal a serious problem, such as severe abdominal pain, persistent vomiting, signs of pancreatitis, or symptoms of a gallbladder problem, contact your prescriber or seek urgent care rather than waiting for a coverage decision. A coverage denial is never a reason to obtain the drug from an unverified or compounded source without a prescriber's direct involvement, since compounded semaglutide products are not FDA-approved and carry different quality and dosing-accuracy uncertainties than the branded product.